Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.
暂无分享,去创建一个
Marion Smits | Bradley J Erickson | Jayashree Kalpathy-Cramer | Martin Bendszus | Michael V Knopp | Benjamin M Ellingson | Timothy F Cloughesy | Whitney B Pope | Susan Chang | Paula Jacobs | Dewen Yang | Michael Weller | Gregory Goldmacher | Elizabeth Gerstner | Mark R Gilbert | Wolfgang Wick | Patrick Y Wen | Susan M. Chang | Sarah J Nelson | Caroline Chung | M. Gilbert | B. Erickson | Jayashree Kalpathy-Cramer | M. Knopp | P. Wen | S. Nelson | J. Boxerman | M. J. van den Bent | M. Weller | T. Cloughesy | L. Shankar | W. Wick | D. Barboriak | M. Vogelbaum | E. Gerstner | E. Galanis | S. Cha | W. Pope | M. Smits | M. Bendszus | B. Ellingson | C. Chung | G. Goldmacher | Dewen Yang | P. Jacobs | Martin J van den Bent | Evanthia Galanis | B. Alexander | Michael Vogelbaum | Jerrold Boxerman | Daniel Barboriak | Brian Alexander | Lalitha Shankar | Soonme Cha | W K Al Yung | W. Yung
[1] Timothy F Cloughesy,et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.
[2] Toshinori Hirai,et al. Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.
[3] K. Yamashita,et al. 3D Turbo Spin-Echo Sequence with Motion-Sensitized Driven-Equilibrium Preparation for Detection of Brain Metastases on 3T MR Imaging , 2011, American Journal of Neuroradiology.
[4] J. Economou,et al. Nuclear magnetic resonance studies of several experimental and human malignant tumors. , 1973, Cancer research.
[5] Sharmila Majumdar,et al. A comparative study at 3 T of sequence dependence of T2 quantitation in the knee. , 2008, Magnetic resonance imaging.
[6] Yasuhiro Inoue,et al. Localization and trafficking of membrane-bound MMPs , 2001 .
[7] J. Marks,et al. Prognostic significance of lesion size for glioblastoma multiforme. , 1979, Radiology.
[8] S B Green,et al. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. M. Taylor,et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.
[10] I. Tannock,et al. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. A. van der Laak,et al. Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. , 1998, Human pathology.
[12] S. Holtås,et al. Time-dependency in brain lesion enhancement with gadodiamide injection , 1997, Acta radiologica.
[13] Benjamin M Ellingson,et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. , 2014, Radiology.
[14] C. Matula,et al. Magnetic Resonance Imaging Contrast Enhancement of Brain Tumors at 3 Tesla Versus 1.5 Tesla , 2002, Investigative radiology.
[15] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[16] D. DeLong,et al. Bidimensional measurements in brain tumors: assessment of interobserver variability. , 2009, AJR. American journal of roentgenology.
[17] P. Lavin,et al. Studies in variation associated with the measurement of solid tumors , 1980, Cancer.
[18] Norbert Schuff,et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry , 2006, NeuroImage.
[19] H. Kreisman,et al. Problems in radiographic estimation of response to chemotherapy and radiotherapy in small cell lung cancer , 1988, Cancer.
[20] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Holl,et al. A T1-weighted rapid three-dimensional gradient-echo technique (MP-RAGE) in preoperative MRI of intracranial tumours , 1996, Neuroradiology.
[22] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[23] Susan M. Chang,et al. Impact of imaging measurements on response assessment in glioblastoma clinical trials. , 2014, Neuro-oncology.
[24] Michael Weller,et al. Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.
[25] F Barkhof,et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma , 2003, Neurology.
[26] B. Escudier,et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] F. Ståhlberg,et al. Brain lesion contrast in MR imaging , 1997, Acta radiologica.
[28] Benjamin M Ellingson,et al. Pros and cons of current brain tumor imaging. , 2014, Neuro-oncology.
[29] W. Nitz,et al. MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence--initial experience in the brain. , 1992, Radiology.
[30] A Gregory Sorensen,et al. Emerging techniques and technologies in brain tumor imaging. , 2014, Neuro-oncology.
[31] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[32] K. Aldape,et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[33] D. Medina,et al. Relationship between hydration and proton nuclear magnetic resonance relaxation times in tissues of tumor-bearing and non-tumor-bearing mice: implications for cancer detection. , 1974, Journal of the National Cancer Institute.
[34] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[35] Bruce Fischl,et al. Impact of MRI head placement on glioma response assessment , 2014, Journal of Neuro-Oncology.
[36] R. Damadian. Tumor Detection by Nuclear Magnetic Resonance , 1971, Science.
[37] Walter J Curran,et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Hopper,et al. Analysis of interobserver and intraobserver variability in CT tumor measurements. , 1996, AJR. American journal of roentgenology.
[39] Bradley J Erickson,et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. , 2006, Neuro-oncology.
[40] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[41] B. Condon,et al. Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? , 2005, AJNR. American journal of neuroradiology.
[42] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Mrugala,et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.
[44] Susan M. Chang,et al. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). , 2014, Neuro-oncology.
[45] D. Atkinson,et al. Three‐dimensional MR imaging and display of intracranial disease: Improvements with the MP‐RAGE sequence and gadolinium , 1993, Journal of magnetic resonance imaging : JMRI.
[46] L. Van den Hauwe,et al. Clinical usefulness of contrast-enhanced MP-RAGE of the brain. , 1996 .
[47] J. Heidenreich,et al. Quantitative contrast ratio comparison between T1 (TSE at 1.5T, FLAIR at 3T), magnetization prepared rapid gradient echo and subtraction imaging at 1.5T and 3T. , 2013, Quantitative imaging in medicine and surgery.
[48] James M Provenzale,et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. , 2002, Radiology.
[49] C. Jack,et al. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.
[50] S. Schoenberg,et al. Brain Tumor Enhancement in MR Imaging at 3 Tesla: Comparison of SNR and CNR Gain Using TSE and GRE Techniques , 2007, Investigative radiology.
[51] P. M. Parizel,et al. Clinical usefulness of contrast-enhanced MP-RAGE of the brain , 2005, Neuroradiology.
[52] P. LaViolette,et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.
[53] P S Albert,et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. , 2001, Journal of the National Cancer Institute.
[54] Owen Carmichael,et al. Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.
[55] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[56] P. Black,et al. Microvessel density is a prognostic indicator for patients with astroglial brain tumors , 1996, Cancer.
[57] P. Choyke,et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.
[58] L. H. Bennett,et al. Recognition of Cancer in vivo by Nuclear Magnetic Resonance , 1972, Science.
[59] G A Lloyd,et al. Subtraction gadolinium enhanced magnetic resonance for head and neck imaging. , 1993, The British journal of radiology.
[60] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[61] J W Sayre,et al. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. , 2000, AJNR. American journal of neuroradiology.
[62] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[63] V M Runge,et al. Clinical comparison of three‐dimensional MP‐RAGE and FLASH techniques for MR imaging of the head , 1991, Journal of magnetic resonance imaging : JMRI.
[64] Rémy Guillevin,et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. , 2012, Neuro-oncology.